TradingKey - On July 28 ET, Berkshire Hathaway Class B shares (BRK.B) closed at $512.37, marking the highest closing price since November 28 of last year ($513.81), but remaining approximately 5% below the all-time closing high of $539.80 reached on May 2, 2025. Class A shares (BRK.A) also trended higher, closing at $768,010 on Tuesday, with an all-time high of $809,350 recorded on the same day.

TradingKeyMon, Aug 3

NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery

TradingKey - NovoCure surged to $19.91 after Q2 2026 earnings released this morning. Revenue consensus was $172M growing 8.6% YoY. The story is Optune Pax's FDA approval and multi-indication expansion after June's TRIDENT trial disappointment. Here is the setup.

TradingKeyFri, Jul 24

UnitedHealth (UNH) Beat Q2 EPS by 30% and the Medical Cost Ratio Hit a Two-Year Low; Is $454 the Target?

TradingKey - UnitedHealth beat Q2 2026 EPS by 30%, reported an 86.7% medical cost ratio (down from 89.4%), and raised full-year guidance to $19.50 to $20.00 per share. At $425 in a rising channel, here’s what $454 needs and why the DOJ investigation still matters.

TradingKeyFri, Jul 17

Intuitive Surgical (ISRG) Down 30% This Year; Can Tonight’s Q2 Earnings Reverse the Bearish Channel?

TradingKey - Intuitive Surgical reports Q2 2026 after the close today with consensus EPS of $2.50. The stock is down 30% this year despite beating estimates four quarters running. At $389 in a descending channel, tonight’s print is the catalyst the chart needs.

TradingKeyThu, Jul 16

TradingKey The Week on Wall Street: Ceasefire Hopes, AI Boom Lift US Stocks to New Highs; Inflation and Policy Risks Remain

TradingKey - US markets were closed on Monday, May 25, for Memorial Day. Geopolitical optimism surrounding US-Iran diplomatic talks continued to influence markets, with hopes for a ceasefire or deal regarding the Strait of Hormuz. Kevin Warsh, who was sworn in as Federal Reserve Chair on Friday, May

TradingKeyMon, Jun 1

Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%

TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKeyThu, May 28